<DOC>
	<DOCNO>NCT02074839</DOCNO>
	<brief_summary>The purpose Phase I , multicenter study evaluate safety , pharmacokinetics , pharmacodynamics clinical activity AG-120 advance hematologic malignancy harbor IDH1 mutation . The first portion study dose escalation phase cohorts patient receive ascend oral dos AG-120 determine maximum tolerate dose ( MTD ) and/or recommend Phase II dose . The second portion study dose expansion phase four cohort patient receive AG-120 evaluate safety , tolerability , clinical activity recommend Phase II dose . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>Study Orally Administered AG-120 Subjects With Advanced Hematologic Malignancies With IDH1 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Subject must ≥18 year age . Subjects must document IDH1 R132 genemutated advanced hematologic malignancy base local central evaluation . Subjects must amenable serial bone marrow biopsy , peripheral blood sampling , urine sampling study . Subjects must ECOG PS 0 2 . Platelet count ≥20,000/µL ( Transfusions achieve level allow ) . Subjects must adequate hepatic function evidence : Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) ≤3.0 × ULN , unless consider due leukemic disease serum total bilirubin ≤1.5 x upper limit normal ( ULN ) , unless consider due Gilbert 's disease leukemic disease Subjects must adequate renal function evidence serum creatinine ≤2.0 × ULN creatinine clearance &gt; 40mL/min base CockroftGault glomerular filtration rate ( GFR ) Subjects must recover clinically relevant toxic effect prior surgery , radiotherapy , therapy intend treatment cancer . Female subject reproductive potential must negative serum pregnancy test within 7 day prior start therapy first day study drug administration . Key Subjects undergone hematopoietic stem cell transplant ( HSCT ) within 60 day first dose AG120 , subject immunosuppressive therapy post HSCT time screening , clinically significant graftversushost disease ( GVHD ) . ( The use stable dose oral steroid post HSCT and/or topical ongoing skin GVHD permit . ) Subjects receive systemic anticancer therapy radiotherapy &lt; 14 day prior first day study drug administration . ( Hydroxyurea allow prior enrollment start AG120 ) . Subjects receive investigational agent &lt; 14 day prior first day study drug administration . Subjects pregnant breastfeeding . Subjects active severe infection unexplained fever &gt; 38.5°C screen visit first day study drug administration ( discretion Investigator , subject tumor fever may enrol ) . Subjects New York Heart Association ( NYHA ) Class III IV congestive heart failure LVEF &lt; 40 % echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan within approximately 28 day C1D1 . Subjects history myocardial infarction within last 6 month screen . Subjects know unstable uncontrolled angina pectoris . Subjects know history severe and/or uncontrolled ventricular arrhythmia . Subjects know unstable uncontrolled angina pectoris . Subjects heartrate correct QT ( QTc ) interval ≥450 m factor increase risk QT prolongation arrhythmic event . Patients take medication know prolong QT interval Subjects know infection human immunodeficiency virus ( HIV ) active hepatitis B C. Subjects clinical symptom suggest active central nervous system ( CNS ) leukemia know CNS leukemia . Evaluation cerebrospinal fluid require clinical suspicion CNS involvement leukemia screen . Subjects immediately lifethreatening , severe complication leukemia uncontrolled bleeding , pneumonia hypoxia shock , and/or disseminate intravascular coagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>IDH</keyword>
	<keyword>Untreated AML</keyword>
	<keyword>IDH1</keyword>
	<keyword>relapse AML</keyword>
	<keyword>refractory AML</keyword>
</DOC>